EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies

Nada Abla iD, Lisa M Almond iD, Jennifer J Bonner iD, Naomi Richardson iD, Timothy N C Wells iD, Jörg J Möhrle iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13865 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Nada Abla und 5 weiteren Autor:innen. Beteiligte Einrichtung: MMV Medicines for Malaria Venture, Geneva, Switzerland. Hauptthemen laut MEDLINE: Antimalarials, Drug Repositioning, Amodiaquine, COVID-19 Drug Treatment. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The urgent need for safe, efficacious, and accessible drug treatments to treat coronavirus disease 2019 (COVID‐19) prompted a global effort to evaluate drug repurposing opportunities. Pyronaridine and amodiaquine are both components of approved antimalarials with in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). In vitro activity does not always translate to clinical efficacy across a therapeutic dose range. This study applied available, verified, physiologically based pharmacokinetic (PBPK) models for pyronaridine, amodiaquine, and its active metabolite N‐desethylamodiaquine (DEAQ) to predict drug concentrations in lung tissue relative to plasma or blood in the default healthy virtual population. Lung exposures were compared to published data across the reported range of in vitro EC 50 values against SARS‐CoV‐2. In the multicompartment permeability‐limited PBPK model, the predicted total C max in lung mass for pyronaridine was 34.2 μM on Day 3, 30.5‐fold greater than in blood (1.12 μM) and for amodiaquine was 0.530 μM, 8.83‐fold greater than in plasma (0.060 μM). In the perfusion‐limited PBPK model, the DEAQ predicted total C max on Day 3 in lung mass (30.2 μM) was 21.4‐fold greater than for plasma (1.41 μM). Based on the available in vitro data, predicted drug concentrations in lung tissue for pyronaridine and DEAQ, but not amodiaquine, appeared sufficient to inhibit SARS‐CoV‐2 replication. Simulations indicated standard dosing regimens of pyronaridine‐artesunate and artesunate‐amodiaquine have potential to treat COVID‐19. These findings informed repurposing strategies to select the most relevant compounds for clinical investigation in COVID‐19. Clinical data for model verification may become available from ongoing clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsDrug RepositioningAmodiaquineCOVID-19 Drug TreatmentSARS-CoV-2LungHumansNaphthyridinesModels, BiologicalCOVID-19Antiviral AgentsComputer Simulation

Substanzen

AntimalarialsAmodiaquinepyronaridineNaphthyridinesdesethylamodiaquineAntiviral Agents

Autor:innen und Institutionen

  • MMV Medicines for Malaria Venture, Geneva, Switzerland.
  • Certara UK Ltd, Sheffield, UK.
  • Magenta Communications Ltd, Abingdon, UK.

ORCID-Profile: Nada Abla, Lisa M Almond, Jennifer J Bonner, Naomi Richardson, Timothy N C Wells, Jörg J Möhrle

Zitieren

APA

Abla, N., Almond, L. M., Bonner, J. J., Richardson, N., Wells, T. N. C., & Möhrle, J. J. (2024). PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies. Clinical and Translational Science. https://doi.org/10.1111/cts.13865

Vancouver

Abla N, Almond LM, Bonner JJ, Richardson N, Wells TNC, Möhrle JJ. PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies. Clinical and Translational Science. 2024. doi:10.1111/cts.13865

BibTeX
@article{Abla2024,
  author = {Abla, Nada and Almond, Lisa M and Bonner, Jennifer J and Richardson, Naomi and Wells, Timothy N C and Möhrle, Jörg J},
  title = {PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13865}
}
Kostenlos starten →